You are being redirected to the home page of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) which acquired Illumigen Biosciences, Inc. effective December 26, 2007. Cubist is moving forward with Illumigen's lead compound, IB657, a pre-clinical stage protein therapeutic in development for the treatment of Hepatitis C Virus (HCV) infections.